Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia (Q73691630)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

familial combined hyperlipidemia

6 November 2019

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

A A Papageorgiou

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

H A Hatzikonstandinou

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

T P Didangelos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

M V Carina

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

D F Kranitsas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A G Kontopoulos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 September 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

608-613

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

Familial lipoprotein disorders in patients with premature coronary artery disease

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Combination drug therapy for familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Efficacy and long-term adverse effect pattern of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Lovastatin decreases coenzyme Q levels in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900430-X

10.1016/S0002-9149(97)00430-X

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9294990%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference